A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

PHASE3TerminatedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

March 7, 2025

Study Completion Date

March 7, 2025

Conditions
Ulcerative Colitis
Interventions
DRUG

Ozanimod

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (51)

0

Local Institution - 0061, Changzhou

114

Local Institution - 0060, Taipei City

235

Local Institution - 0058, New Taipei City

333

Local Institution - 0055, Taoyuan District

407

Local Institution - 0059, Taichung

10002

Local Institution - 0056, Taipei

11217

Local Institution - 0057, Taipei

40447

Local Institution - 0001, Taichung

50006

Local Institution - 0054, Changhua County

102206

Local Institution - 0052, Beijing

110004

Local Institution - 0010, Shenyang

200025

Local Institution - 0035, Shanghai

200032

Local Institution - 0041, Shanghai

200092

Local Institution - 0034, Shanghai

200120

Local Institution - 0053, Shanghai

210000

Local Institution - 0024, Nanjing

210029

Local Institution - 0045, Nanjing

212000

Local Institution - 0042, Zhenjiang

213003

Local Institution - 0046, Changzhou

214023

Local Institution - 0044, Wuxi

215004

Local Institution - 0018, Suzhou

215006

Local Institution - 0009, Suzhou

230071

Local Institution - 0012, Hefei

241001

Local Institution - 0013, Wuhu

250014

Local Institution - 0039, Jinan

300052

Local Institution - 0031, Tianjin

300121

Local Institution - 0047, Tianjin

310016

Local Institution - 0030, Hangzhou

350005

Local Institution - 0048, Fuzhou

361004

Local Institution - 0011, Xiamen

400014

Local Institution - 0050, Chongqing

410008

Local Institution - 0027, Changsha

410013

Local Institution - 0022, Changsha

430022

Local Institution - 0040, Wuhan

430030

Local Institution - 0037, Wuhan

430060

Local Institution - 0033, Wuhan

510080

Local Institution - 0020, Guangzhou

510180

Local Institution - 0036, Guangzhou

510280

Local Institution - 0028, Guangzhou

510515

Local Institution - 0019, Guangzhou

510655

Local Institution - 0008, Guangzhou

524004

Local Institution - 0004, Zhanjiang

541001

Local Institution - 0051, Guilin

610041

Local Institution - 0032, Chengdu

610072

Local Institution - 0025, Chengdu

650034

Local Institution - 0049, Kunming

710032

Local Institution - 0029, Xi'an

710038

Local Institution - 0026, Xi'an

050000

Local Institution - 0007, Shijiazhuang

050011

Local Institution - 0006, Shijiazhuang

030001

Local Institution - 0015, Taiyuan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05644665 - A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Biotech Hunter | Biotech Hunter